Sign In
Buy CCXI
$10.24
+0.0150 (+0.147%)
At Close: Jun 03, 2026
ChemoCentryx, Inc. (CCXI) announced today the completion of its follow-on offering of 5,200,000 shares of its common stock. ChemoCentryx also announced today that the underwriters of its follow-on
ChemoCentryx Inc (NASDAQ:CCXI) Shares Bought by Federated Hermes Inc.
07:00am, Sunday, 14'th Jun 2020
Federated Hermes Inc. raised its holdings in ChemoCentryx Inc (NASDAQ:CCXI) by 128.1% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commis
Hedge Funds Have Never Been This Bullish On ChemoCentryx Inc (CCXI)
01:49pm, Friday, 12'th Jun 2020
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).
ChemoCentryx Prices Public Offering of Common Stock
01:33am, Thursday, 11'th Jun 2020
ChemoCentryx, Inc. (CCXI) announced today that it has priced an underwritten public offering of 5,200,000 shares of its common stock at a price to the public of $58.00 per share. The gross proceeds t
ChemoCentryx Announces Proposed Public Offering of Common Stock
08:08pm, Wednesday, 10'th Jun 2020
ChemoCentryx, Inc. (CCXI) announced today that it has commenced an underwritten public offering of its common stock. In connection with this offering, ChemoCentryx plans to grant the underwriters a 3
ChemoCentryx Files For Mixed Offering, Size Not Disclosed
08:05pm, Wednesday, 10'th Jun 2020Small Caps Build Steam And Biotechs Remain Well-Positioned
02:15pm, Wednesday, 10'th Jun 2020
Economic optimism has broadened the market rally. Small caps had lagged significantly and are now catching-up as they narrow the performance gap. The Federal Re
ChemoCentryx: Avacopan's Attractive Value Proposition (NASDAQ:CCXI)
10:00am, Monday, 08'th Jun 2020
ChemoCentryx management is still delivering strong execution. Despite the recent announcement that the LUMINA-1 trial failed to meet its primary endpoint, there
MOUNTAIN VIEW, Calif., June 03, 2020 -- ChemoCentryx, Inc., (NASDAQ: CCXI) today announced presentations highlighting outcomes of the Company’s Phase III ADVOCATE trial as part.
ChemoCentryx Phase III ADVOCATE Trial of Avacopan in ANCA-Associated Vasculitis Highlighted in ...
12:00am, Wednesday, 03'rd Jun 2020Top Small Cap Stocks for June 2020
05:38pm, Friday, 29'th May 2020
Small cap stocks are listed companies that have market capitalizations typically ranging from $300 million to $2 billion. Since the share prices of these companies can have big fluctuations over a sh
8-K: ChemoCentryx, Inc.
05:54am, Friday, 29'th May 2020
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT (EDGAR Online via COMTEX) --
Pursuant to Section 13 OR 15(d)...
The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant
12:00am, Friday, 29'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 28)
ADC Therapeutics SA (NYSE:...
The Daily Biotech Pulse: PhaseBio To Start Potential Pivotal COVID-19 Trial, Immunomedics CEO Quits, Tetraphase Receives Sweetened Offer
12:00am, Thursday, 28'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 27)
ADC Therapeutics SA (NYSE:...
